Skip to main content

3 Result(s)

within David E. Coutant Remove this filter

and

  1. Article

    Open Access

    Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog® (Lispro) in Patients with Type 2 Diabetes Mellitus: A Phase I Randomised, Crossover Study

    Ultra rapid lispro (URLi) is a novel insulin lispro formulation developed to more closely match physiological insulin secretion and improve postprandial glucose control. This study compared the insulin lispro ...

    Jennifer Leohr, Mary Anne Dellva, David E. Coutant… in Clinical Pharmacokinetics (2020)

    Download PDF (874 KB) View Article

  2. Article

    Open Access

    Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog® (Lispro) in Younger Adults and Elderly Patients with Type 1 Diabetes Mellitus: A Randomised Controlled Trial

    Ultra rapid lispro (URLi) is a novel insulin lispro formulation developed to more closely match physiological insulin secretion and improve postprandial glucose control. This study compared the pharmacokinetic...

    Helle Linnebjerg, Qianyi Zhang, Elizabeth LaBell… in Clinical Pharmacokinetics (2020)

    Download PDF (958 KB) View Article

  3. Article

    Open Access

    Bioequivalence of Ultra Rapid Lispro (URLi) U100 and U200 Formulations in Healthy Subjects

    Ultra rapid lispro (URLi) is a novel insulin lispro formulation that was developed to more closely match physiological insulin secretion. The aims of this study were to demonstrate the bioequivalence (BE) of a...

    Helle Linnebjerg, Elizabeth Smith LaBell, Mary Anne Dellva… in Diabetes Therapy (2020)

    Download PDF (513 KB) View Article